There are limited specific treatment options requiring specialist care for most patients, improving CKD prognosis [29, 30], apart from hypertension and diabetes management, which are recommended regardless of kidney function, and despite recent progress with Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors. Here, SLC5A2 is linked to hypertensive disorder.